EUR 0.46
(15.0%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 27.05 Million EUR | -1.17% |
2022 | 27.33 Million EUR | 45.11% |
2021 | 18.83 Million EUR | 73.21% |
2020 | 10.87 Million EUR | -16.44% |
2019 | 13.01 Million EUR | -9.98% |
2018 | 14.45 Million EUR | 26.25% |
2017 | 11.45 Million EUR | 382.12% |
2016 | 2.37 Million EUR | 31.98% |
2015 | 1.79 Million EUR | -41.19% |
2014 | 3.06 Million EUR | 65.84% |
2013 | 1.84 Million EUR | 53.33% |
2012 | 1.2 Million EUR | 102.61% |
2011 | 593.93 Thousand EUR | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q2 | 3.01 Million EUR | 0.0% |
2023 Q2 | 14.35 Million EUR | 0.0% |
2023 Q4 | 13.12 Million EUR | 0.0% |
2023 FY | 27.01 Million EUR | -1.17% |
2022 Q2 | 13.71 Million EUR | 0.0% |
2022 FY | 27.33 Million EUR | 45.11% |
2022 Q4 | 13.61 Million EUR | 0.0% |
2021 Q2 | 7.58 Million EUR | 0.0% |
2021 Q4 | 11.25 Million EUR | 0.0% |
2021 FY | 18.83 Million EUR | 73.21% |
2020 Q4 | 5.5 Million EUR | 0.0% |
2020 Q2 | 5.37 Million EUR | 0.0% |
2020 FY | 10.87 Million EUR | -16.44% |
2019 Q2 | 6.25 Million EUR | 0.0% |
2019 FY | 13.01 Million EUR | -9.98% |
2019 Q4 | 6.74 Million EUR | 0.0% |
2018 Q2 | 7.35 Million EUR | 0.0% |
2018 Q4 | 7.1 Million EUR | 0.0% |
2018 FY | 14.45 Million EUR | 26.25% |
2017 FY | 11.45 Million EUR | 382.12% |
2017 Q4 | 5.98 Million EUR | 0.0% |
2017 Q2 | 5.46 Million EUR | 0.0% |
2016 FY | 2.37 Million EUR | 31.98% |
2016 Q2 | 5.37 Million EUR | 0.0% |
2016 Q4 | 3 Million EUR | 0.0% |
2015 FY | 1.79 Million EUR | -41.19% |
2015 Q4 | 140.17 Thousand EUR | 0.0% |
2015 Q2 | 1.93 Million EUR | 0.0% |
2014 FY | 3.06 Million EUR | 65.84% |
2014 Q4 | 1.79 Million EUR | 333.64% |
2014 Q3 | -770.24 Thousand EUR | -159.41% |
2014 Q2 | 1.29 Million EUR | 268.32% |
2014 Q1 | -770.24 Thousand EUR | 0.0% |
2013 Q3 | -411.68 Thousand EUR | 0.0% |
2013 FY | 1.84 Million EUR | 53.33% |
2013 Q4 | -770.24 Thousand EUR | -87.09% |
2013 Q1 | -411.68 Thousand EUR | 0.0% |
2013 Q2 | -411.68 Thousand EUR | 0.0% |
2012 Q4 | -411.68 Thousand EUR | -66.79% |
2012 FY | 1.2 Million EUR | 102.61% |
2012 Q1 | -246.83 Thousand EUR | 0.0% |
2012 Q2 | -246.83 Thousand EUR | 0.0% |
2012 Q3 | -246.83 Thousand EUR | 0.0% |
2011 FY | 593.93 Thousand EUR | 0.0% |
2011 Q4 | -246.83 Thousand EUR | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
ABIONYX Pharma SA | 4.17 Million EUR | -547.683% |
ABIVAX Société Anonyme | 127.37 Million EUR | 78.761% |
Adocia SA | 15.62 Million EUR | -73.099% |
Aelis Farma SA | 18.81 Million EUR | -43.757% |
Biophytis S.A. | 14.33 Million EUR | -88.751% |
Advicenne S.A. | 8.21 Million EUR | -229.321% |
genOway Société anonyme | 16.73 Million EUR | -61.628% |
IntegraGen SA | 5.35 Million EUR | -405.439% |
Medesis Pharma S.A. | 1.56 Million EUR | -1629.143% |
Neovacs S.A. | 10.34 Million EUR | -161.551% |
NFL Biosciences SA | 4.37 Million EUR | -518.462% |
Plant Advanced Technologies SA | 2.76 Million EUR | -878.487% |
Quantum Genomics Société Anonyme | 1.71 Million EUR | -1474.752% |
Theranexus Société Anonyme | 3 Million EUR | -800.293% |
TME Pharma N.V. | 5.49 Million EUR | -392.154% |
Valbiotis SA | 9.86 Million EUR | -174.128% |
TheraVet SA | 1.64 Million EUR | -1545.288% |
Valerio Therapeutics Société anonyme | 20.32 Million EUR | -33.138% |
DBV Technologies S.A. | 89.4 Million EUR | 69.741% |
Genfit S.A. | 54.8 Million EUR | 50.636% |
GeNeuro SA | 14.35 Million EUR | -88.432% |
Innate Pharma S.A. | 64.57 Million EUR | 58.102% |
Inventiva S.A. | 120.18 Million EUR | 77.49% |
MaaT Pharma SA | 21.59 Million EUR | -25.26% |
MedinCell S.A. | 32.92 Million EUR | 17.825% |
Nanobiotix S.A. | 58.92 Million EUR | 54.089% |
OSE Immunotherapeutics SA | 23.58 Million EUR | -14.688% |
Poxel S.A. | 28.76 Million EUR | 5.949% |
GenSight Biologics S.A. | 32.66 Million EUR | 17.166% |
Transgene SA | 31.23 Million EUR | 13.376% |
Valneva SE | 134.92 Million EUR | 79.949% |